← Back to Company DatabaseVisit Website
Legend Biotech
CAR-T cell therapy developer for multiple myeloma and beyond.
PublicSomerset, NJFounded 2014
About
Legend Biotech is a global biopharmaceutical company developing novel cell therapies for cancer. Its lead product Carvykti (ciltacabtagene autoleucel), developed in partnership with Johnson & Johnson, is an FDA-approved CAR-T therapy for relapsed or refractory multiple myeloma. The company is expanding its cell therapy pipeline across additional cancer indications.
Total Funding
$500MKey Product
Carvykti (ciltacabtagene autoleucel) CAR-T therapyGeography
North AmericaKey Investors
Johnson & JohnsonBaker BrothersHillhouse Capital
Focus Areas
Treatment (Therapeutics)
Technology
Cell TherapyImmunotherapy
Cancer Types
Blood Cancers
Last updated: Feb 4, 2026